---
layout: default
title: Home
---

# Welcome to the Oncology Treatment Switch Workstream

The Oncology Treatment Switch Workstream aims to bring together statisticians, clinicians, and regulatory experts to tackle one of the most challenging aspects of modern clinical trials in oncology: **treatment switching**. This Workstream is an initiative of the Statistical Methods in Oncology Scientific Working Group under ASA Biopharmaceutical Section.


<!--
When patients switch from their assigned treatment to another therapy (often due to disease progression or safety concerns), traditional intent-to-treat analyses may not provide the most relevant estimates of treatment efficacy. Our workstream develops, validates, and promotes statistical methods that can properly adjust for this switching while maintaining scientific rigor.

**Why This Matters:**
- Treatment switching is increasingly common in oncology trials
- Regulatory agencies need robust methods for evaluation
- Patients and clinicians need clear efficacy estimates
- Statistical community needs validated, accessible tools
-->

Join us in advancing the science of treatment switching analysis!

<!-- <button class="collapsible">üìã Objectives</button>
<div class="collapsible-content">
-->
# OUr Mission
  <p>Treatment switching is a common occurrence in oncology clinical trials and is characterized by patients switching from control therapy to treatment therapy or vice versa during a clinical study. The occurrence of treatment switching amongst a large number of patients confounds and complicates a standard ITT based analysis of treatment efficacy, especially for long term outcomes such as overall survival and adjuvant-based disease-free survival.</p>
  
  <p>In the past decade of rapid oncology development for immuno-based and targeted-based therapies, treatment switching has been a regular occurrence in clinical trials and has led to several key oncologic drug advisory committee meetings. Yet, the topic has received only limited development in the academic and methodologic space and no organized group has yet emerged to bring a structured foundation for future research endeavors.</p>
  
  <p>In order to help standardize and promote treatment switching methodological research and ideas, we propose to start a Treatment Switch workstream with membership from FDA, academic, and industry leaders involved in methodology in this space. We have three major goals: </p>
  
1. **Tutorial**: To write and publish a tutorial for treatment switching in the peer-reviewed journal Statistics in Medicine. Have received early feedback from editor Paul Albert that the journal would welcome the approach, but need to go through standard peer-review process via associate editor.
  
2. **Trial Implementation**: To do fundamental research on practical matters related to treatment switching and its occurrence in clinical trials. Topics to include simulations on the effect of crossover, proposals for how to pre-specify such analyses in protocols, methods and literature reviews on subsequent therapies.
  
3. **Code Standardization**: To work towards a well-rounded repository of code with examples to implement most standard models for such work.

<!--
</div>
-->
  
<!--
<button class="collapsible">üë• Sub-teams</button>
<div class="collapsible-content">
-->
<!--
<h3>Workstream Organization</h3>
  <p>Our workstream is organized into specialized sub-teams focused on different aspects of treatment switching methodology.</p>
-->   
# Sub-teams  
  1. **Tutorial Sub-team:**    
    The tutorial subteam focuses on case studies and method comparisons across different treatment switching approaches. It is currently preparing a tutorial manuscript.    
    **Leads:**  Ananya Roy (Merck)

2. **Novel Method and Trial Implementation Sub-team:**    
    The new methods subteam focuses on emerging methodologies and is currently comparing different data generation approaches for treatment switching scenarios. The practical considerations subteam focuses on factors influencing treatment switching methods, including the impact of switcher proportion, method selection, non-statistical considerations, and sensitivity analyses. It also includes simulations to inform study design and guide appropriate analysis methods.    
    **Leads:** Yufei Wang (Eli Lily) and Ray Lin (Genentech/Roche)
   
 3. **Code Standardization Sub-team:**    
    The code standardization subteam aims to provide validated, ready to use R and SAS code for commonly used treatment switching methods, including IPCW, IPE, MSM, RPSFT, and the TSE. It also collaborates with other subteams on website development.    
    **Leads:** Kaifeng Lu (BeOne Medicines) and Ray Lin (Genentech/Roche)


<!--
<button class="collapsible">üìà Recent Updates</button>
<div class="collapsible-content">
  <h3>Latest Developments</h3>
  
  <h4>Recent Milestones:</h4>
  <ul>
    <li><strong>Q4 2024:</strong> Published package on CRAN </li>

  </ul>
  
  <h4>Upcoming Activities:</h4>
 
</div>
-->
<!--
<button class="collapsible">üë®‚Äçüíº Get Involved</button>
<div class="collapsible-content">
-->
# Join Our Community
  We welcome statisticians, clinicians, and researchers interested in advancing treatment switching methodology. Contact us at [trt.switch@gmail.com].  
  <ul>
    <li><strong>Join a Sub-team:</strong> Contact sub-team leads to contribute to specific areas</li>
    <li><strong>Attend Meetings:</strong> Virtual seminars open to all members</li>
    <li><strong>Contribute to Validation:</strong> Help test methods on real-world datasets</li>
    <li><strong>Share Experience:</strong> Present case studies from your trials</li>
    <li><strong>Review Materials:</strong> Provide feedback on guidance documents</li>
  </ul>
   <p>**Contact us at [workstream-email@asa.org]**</p>
  
<!--
</div>
## Quick Navigation

<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 1rem; margin: 2rem 0;">
  
  <div style="text-align: center; padding: 1rem; border: 1px solid #dee2e6; border-radius: 8px;">
    <h3>üë• Members</h3>
    <p>Meet our workstream team members </p>
    <a href="{{ '/members' | relative_url }}" class="btn">View Team</a>
  </div>

  <div style="text-align: center; padding: 1rem; border: 1px solid #dee2e6; border-radius: 8px;">
    <h3>üìä Methods</h3>
    <p>Methods adjusting for treatment switching</p>
    <a href="{{ '/methods' | relative_url }}" class="btn">Learn More</a>
  </div>
    
  <div style="text-align: center; padding: 1rem; border: 1px solid #dee2e6; border-radius: 8px;">
    <h3>üéì Seminars</h3>
    <p>Educational webinars</p>
    <a href="{{ '/seminars' | relative_url }}" class="btn">View Schedule</a>
  </div>
  
  <div style="text-align: center; padding: 1rem; border: 1px solid #dee2e6; border-radius: 8px;">
    <h3>üìö Resources</h3>
    <p>Training materials and publications</p>
    <a href="{{ '/resources' | relative_url }}" class="btn">Explore</a>
  </div>
  
  <div style="text-align: center; padding: 1rem; border: 1px solid #dee2e6; border-radius: 8px;">
    <h3>üì¶ R Package</h3>
    <p>Download our R package</p>
    <a href="https://github.com/ShreyaSreeram27/trtswitch" class="btn" target="_blank">CRAN</a>
  </div>

</div>
-->




